Waldenström's Macroglobulinemia
2
Pipeline Programs
1
Companies
2
Clinical Trials
2 recruiting
1
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
2
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Small Molecule
2100%
On Market (1)
Approved therapies currently available
Competitive Landscape
1 companies ranked by most advanced pipeline stage
BeOne MedicinesCA - San Carlos
2 programs1
ZanubrutinibPhase 4Small Molecule1 trial
ZanubrutinibN/ASmall Molecule1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2022
2023
2024
2025
2026
2027
2028
BeOne MedicinesZanubrutinib
BeOne MedicinesZanubrutinib
Clinical Trials (2)
A Study to Evaluate the Efficacy and Safety of Zanubrutinib in Chinese Adults With Treatment-Naive Waldenström Macroglobulinemia
Start: Oct 2025Est. completion: Oct 2028
Phase 4Recruiting
Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular Lymphoma
Start: Apr 2022Est. completion: Aug 2028
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 actively recruiting trials
1 companies competing in this space